<DOC>
	<DOCNO>NCT01111890</DOCNO>
	<brief_summary>Subjects dose twice daily 9AM 9PM 12 week . The primary efficacy variable mean change Intraocular Pressure ( IOP ) baseline 12 week . Secondary efficacy variable : % IOP ≤ 18 millimeter mercury ( mmHg ) . Exploratory endpoint : Ocular discomfort scale first dose .</brief_summary>
	<brief_title>Comparison Efficacy AZARGA® Versus COSOPT® Patients With Open-Angled Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>1 . Must least 18 year age . 2 . Must clinical diagnosis ocular hypertension , primary openangle pigment dispersion glaucoma least one eye ( study eye ) . 3 . Must IOP consider safe , eye , way assure clinical stability vision optic nerve throughout study period . 4 . Must willing discontinue use ocular hypotensive agent prior receiving assign study drug Visit 1 , throughout study period . 5 . Must IOP 19 35 mmHg least one eye ( would study eye ) . 6 . For eye include study , intraocular pressure able control pharmacologic therapy study medicine alone . 1 . Known medical history allergy , hypersensitivity poor tolerance component preparation use study deem clinically significant opinion Principal Investigator . 2 . Presence primary secondary glaucoma list inclusion criterion # 2 . 3 . Any abnormality prevent reliable applanation tonometry study eye ( ) . 4 . Risk visual field visual acuity worsen due participation study , investigator 's best judgment . 5 . Progressive retinal optic nerve disease cause . 6 . Use systemic medication know affect IOP ( e.g. , oral betaadrenergic blocker , alphaagonists blocker , angiotensin convert enzyme inhibitor calcium channel blocker ) , stable course 7 day prior Day 1 Visit anticipate change dosage course study . 7 . A condition , opinion Principal Investigator , would interfere optimal participation study , would present special risk subject . 8 . Participation investigational study within 30 day prior Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>